Serum and synovial fluid concentrations of CCL2 (MCP-1) chemokine in patients suffering rheumatoid arthritis and osteoarthritis reflect disease activity

Bratislava Medical Journal

Volumn 110, Issue 10, 2009, Pages 641-646

  Stankovic, A ^a   Slavic, V ^a   Stamenkovic, B ^b   Kamenov, B ^c   Bojanovic, M ^c   Mitrovic, D R ^d  

^a Institute for Prevention and Treatment of Rheumatic Diseases   (Serbia)

^b Institute Dr Simo Milosevic   (Montenegro)

^c University Clinical Center Nis   (Serbia)

^d INSERM   (France)

Author keywords

Corticosteroids; Inflammation; MCP 1; Methotrexate; Osteoarthritis; Rheumatoid arthritis; Serum; Synovial fluid

Indexed keywords

MONOCYTE CHEMOTACTIC PROTEIN 1;

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD; CHEMISTRY; FEMALE; HUMAN; MALE; METABOLISM; MIDDLE AGED; OSTEOARTHRITIS; PATHOLOGY; RHEUMATOID ARTHRITIS; SYNOVIAL FLUID;

ADOLESCENT; ADULT; AGED; ARTHRITIS, RHEUMATOID; CHEMOKINE CCL2; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; SYNOVIAL FLUID; YOUNG ADULT;

EID: 75649126516     PISSN: 00069248     EISSN: 13360345     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Luster AD. Chemokines-chemotactic cytokines that mediate inflammation. New Engl J Med 1998; 338: 436-445.
2. Zlotnik A, Yoshie O. Cemokines: a new classification system and their role in immunity. Immunity 2000; 12: 121-127.
3. Baggiolini M. Chemokines in pathology and medicine. J Intern Med 2001; 250: 91-104.
4. Fernandez EJ, Lolis E. Structure, function and inhibition of chemokines. Rev Pharmacol Toxicol 2002; 42: 469-499.
5. Haringman JJ, Ludikhuize J, Tak PP. Chemokines in joint diseases: the key to inflammation. Ann Rheumat Dis 2004; 63: 1186-1194.
6. Luther SA, Cyster JG. Chemokines as regulators of T cell differentiation. Nat Immunol 2001; 2: 102-107.
7. Moser B, Willimon K. Chemokines: role in inflammation and immune surveillance. Ann Rheumat Dis 2004; 63 (Suppl II): ii84-ii89.
8. Gerard C, Rollins BJ. Chemokines and disease. Nat Immunol 2001; 2: 108-115.
9. Godessart N, Kunkel SL. Chemokines in autoimmune diseases. Curr Opin Immunol 2001; 13: 670-675.
10. Daly C, Rollins BJ. Monocyte chemoattractant protein-1 (CCL1). in inflammatory diseases and adaptive immunity:therpeutic oportunity and controversies. Microcirculation 2003; 10: 247-257.
11. Ajuebor MN, Swan MG, Perretti M. Chemokines a novel therapeutic targets in inflammatory diseases. Biochem Pharmacol 2002; 63: 1191-1196.
12. Moser B. Loetscher P. Lymphocyte traffick control by chemokines. Nat Immunol 2001; 2: 123-128.
13. Muller WA. Leucocyte-endothelial-cell interaction, transmigration and the inflammatory response. Trends Immunol 2003; 24: 327-334.
14. Harris ED Jr. Rheumatoid arthritis. Pathophysiology and implications for thrapy. New Engl J Med 1990; 322: 1277-1289.
15. Lindtqvist C, Eberhardt K, Bendtzen K, Heineg•rd D, Saxne T. Prognostic laboratory markers of joint damage in rhumatoid arthritis. Ann Rheumat Dis 2005; 64: 196-201.
16. Koch AE. Angiogenesis as a target in rheumatoid arthritis. Ann Rheum Dis. 2003; 62 (Suppl 2): ii60-ii70.
17. Coville-Nash P.R., Scott D.J. Angiogenesis in RA: pathogenic and therapeutic implication. Ann Rheum Disc 1992, 51: 919.
18. Fox DA. The role of T cells in the immunopathogenesis of RA: new perspectives. Arthritis Rheum 1997; 40: 598-609.
19. Chatham WW, Edberg JC, Kimberley RP. The role of neutrophils in RA. In: New frontiers in pathogenesis and treatment. New York: Oxford University Press, Inc 2000, 101-112.
20. Katrib A, Tak PP, Bertouch JV et al. Expression of chemokines and matrix metalloproteinases in early rheumatoid arthritis. Rheumatology (Oxford) 2004; 40: 988-994.
21. Sandell LJ, Aigner T. Articular cartilage and changes in arthritis. An introduction: Cell biology of OA. Arthritis Res, 2000; 3: 107-113.
22. Shumacher HR. SF analysis and synovial biopsy. 63-70. In: Kelley WN, Harris ED, Ruddy S, Sledge CB (Eds). Kelley's Textbook of Rheumatology. Saunders publish Co, Philadelphia, 6th ed, 2001.
23. Haywood L, McWilliams DF, Pearson CL et al. Inflammation and angiogenesis in OA. Arthritis Rheum 2003; 48: 2183-2187.
24. Akahoshi T, Wada C, Endo H, Hirota K, Hosaka S, Takagishi K. Expression of monocyte chemotactic and activating factor in RA. Arthritis Rheum 1993; 36: 762-771.
25. Conti P, Reale M, Barbacane RC, Castellani ML, Orso C. Differential production of RANTES and MCP-1 in synovial fluid from the inflamed human knee. Immunol Lett 2002; 80: 105-111.
26. De Benedetti F, Pignatti P, Bernasconi S et al. Interleukin-8 and monocyte chemoattractant protein-1 in patients with juvenile rheumatoid arthritis. Relation to onset types, disease activity, and synovial fluid leucocytes. J Rheumatol 1999; 26: 425-431.
27. Ellingsen T, Buus A, Stemgaard-Pedersen K. Plasma monocyte chemoattractant protein-1 is a marker for joint inflammation in RA. J Rheumatol 2001; 28: 41-46.
28. Koch AE, Kunkel SI, Harlow LA et al. Enhanced production of monocyte chemoattractant protein-1 in RA. J Clin Invest 1992; 90: 772-779.
29. Palacios I, Lopez-Armada MJ, Hernandez P, Sanchez-Pernaute O, Gutierrez S, Miguelez R et al. Tenidap decreases IL-8 and monocyte chemotactic peptide-1 (MCP-1. mRNA expression in the synovial tissue of rabbits with antigen arthritis and in cultured synovial cells. Clin Exp Immunol 1998; 111: 588-596.
30. Hayashida K, Nanki T, Girschick H, Yavuz S, Ochi T, Lypski P. Synovial stromal cells from RA patients attract monocytes by producing MCP-1 and IL-8. Arthrtitis Res 2001; 3: 118-126.
31. Hachicha M, Rathanaswami P, Schall TJ, McColl SR. Production of monocyte chemotactic protein-1 in human type B synoviocytes. Synergistic effect of tumor necrosis factor alpha and interferon-gamma. Arthritis and Rheum 1993; 36: 26-34.
32. Villiger PM, Terkeltaub R, Lotz M. Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol 1992; 149: 722-727.
33. Corrigall VM, Arastu M, Khan S et al. Functional IL-2 receptor beta (CD122. and gamma (CD132. chains are expressed by fibroblastlike synoviocytes: activation by IL-2 stimulates monocyte chemoattrac tant protein-1 production. J Immunol 2001; 166: 4141-4147.
34. Rollins BJ, Yoshimura T, Leonard EJ, Pober JS. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, MCP-l/JS. Am J Pathol 1990; 136: 1229-1233.
35. Katschke KJ jr, Rottman JB, Ruth JH et al. Differential expression of chemokine receptors on peripheral blood, synovial fluid and synovial tissue mnocytes/macrophages in rheumatoid arthritis. Arthritis Rheum 2001; 44: 1022-1032.
36. Loetscher P, Dewald B, Baggiolini M, Seitz M. Monocyte chemoattractant protein-1 and interleukin-8 production by rheumatoid synoviocytes. Effect of anti-rheumatic drugs. Cytokine 1994; 6: 162-170.
37. Villiger PM, Terkeltaub R, Lotz M. Monocyte chemoattractant protein-1 (MCP-1. expression in human articular cartilage. Induction by peptide regulatory factors and differential effects of dexamethasone and retinoic acid. J Clin Invest 1992; 90: 488-496.
38. Pulsatelli L, Dolzani P, Piacentini A et al. Chemokine production by human chondrocytes. J Rheumatol 1999; 26: 1992-2001.
39. Smith MD, Triantafillou S, Parker A, Youssef FF, Caleman M. Synovial membrane inflammation and cytokine production in patients in early OA. J Rheumatol 1997; 24: 365-371.
40. Barzi RM, Mazzetti I, Macor S et al. Flow cytometric analysis of intracellular chemokines in chondrocytes in vivo: constitutive expression and enhancement in OA and RA. FEBS Lett 1999; 455: 238-242.
41. Harigai M, Hara M, Yoshimura T, Leonardi FJ, Inoue K, Kashiwazaki S. Monocyte chemoattractant protein-1 (MCP-1). In: inflammatory joint diseases and its involvement in the cytokine network of rheumatoid synovium. Clin Immunol Immunopathol 1993; 69: 83-91.
42. al-Mughales J, Blyth TH, Hunter JA, Wilkinson PC. The chemo attractant activity of rheumatoid synovial fluid for human lymphocytes is due to multiple cytokines. Clin Exp Immunol 1996; 106: 230-236.
43. Gunn MD, Nelken NA, Liao X, Williams LT. Monocyte chemoattractant protein-1 is sufficient for the chemotaxis of monocytes and lymphocytes in transgenic mice but requires an additional stimulus for inflammatory activation. J Immunol 1997; 158: 376-383.
44. Gu L, Rutledge B, Fiorillo J et al. In vivo properties of monocyte chemoattractant protein-1. J Leukoc Biol 1997; 62: 577-580.
45. Lu B, Rutledge BJ, Gu L et al. Abnormalities in monocyte recruitment and cytokine expression in monocyte chemoattractant protein 1-deficient mice. J Exp Med 1998; 187: 601-608.
46. Rutledge BJ, Rayburn H, Rosenberg R, North RI, Gladue RP, Corless CL, Rollins BJ. High level monocyte chemoattractant prote-in-1 expression in transgenic mice increases their susceptibility to in-tracellular pathogens. J Immunol 1995; 155: 4838-4843.
47. Gu L, Tseng S, Horner RM, Tam C, Loda M, Rollins BI. Control of TH2 polarization by the chemokine monocyte chemoattractant protein-1. Nature 2000; 404: 407-411.
48. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315-324.
49. Felson D, Anderson J, Boers M et al. The American Colledge of Rheumatology preliminary core set of disease activity measures for RA clinical trials. Arthritis Rheumat 1993; 36: 729-724.
50. Kellgren JH, Lawrence LS. The epidemiology of chronic rheumatism. In: Atlas of Standard Radiographs of Arthritis. Vol II, Oxford, Blackwells publ. 1963.